Overview
The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years. With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade.
Full Product Details
Author: J Knäblein
Publisher: Wiley-VCH Verlag GmbH
Imprint: Wiley-VCH Verlag GmbH
Edition: 3rd
Dimensions:
Width: 19.20cm
, Height: 12.10cm
, Length: 25.10cm
Weight: 4.414kg
ISBN: 9783527311842
ISBN 10: 352731184
Pages: 2022
Publication Date: 30 September 2005
Audience:
Professional and scholarly
,
Professional & Vocational
Format: Hardback
Publisher's Status: Unknown
Availability: Out of stock
Reviews
... an authoritative sourcebook dealing with the entire broad range of biopharmaceuticals now available. ... an impressive compilation of outstanding results written by brilliant, creative thinkers who are shaping present and future biotechnology. I am pleased to recommend strongly this complete and comprehensive basic reference source for this new, exciting field to biotechnologists, clinicians, physicians, pharmacists, pharmaceutical chemists, molecular biologists, medicinal chemists, and anyone working in the biotechnological and pharmaceutical industries or in medicinal institutes. It should also be invaluable to undergraduate and graduate students, postdoctoral fellows, and researchers looking for quick, clear, and concise ideas on topics that lie outside their areas of expertise. It also belongs in academic, industrial, and governmental libraries. (The Chemical Educator) This is an extensive and unmatched compilation of comprehensive, in-depth current knowledge and history of biopharmaceuticals...the author is commended for this grand effort. (Veterinary Pathology) I heartly recommend this authoritative, comprehensive reference to this new, exciting field dealing with the entire broad range of available biopharmaceuticals. It will be invaluable to biotechnologists, clinicians, physicians, pharmacists, pharmaceutical chemists, molecular biologists, medicinal chemists and anyone working in the biotechnological and pharmaceutical industries or in medicinal institutes. It should be also be useful for undergraduate and graduate students, postdoctoral fellows, and researchers seeking quick, clear, and concise ideas on topics outside their areas of specialization. it should also find a place in academic, industrial, and governmental libraries. (ChemMedChem) All in all, this is an impressive snapshot of the field. (Journal of Medicinal Chemistry) ... the four volumes represent a highly valuable reference compendium for any practicing scientists interested in this sector of biotechnology. (Chemistry and Industry) Due to the impressive accumulation of outstanding results, presented by brilliant, privileged and creative thinkers, the book reads like the Who is Who of biotechnology. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel Prize laureates Robert Huber, Thomas R. Cech, and Manfred Eigen as well as authors from the world's most famous academic institutes and biotech companies. (BIOforum Europe)
... an authoritative sourcebook dealing with the entire broad range of biopharmaceuticals now available. ... an impressive compilation of outstanding results written by brilliant, creative thinkers who are shaping present and future biotechnology. I am pleased to recommend strongly this complete and comprehensive basic reference source for this new, exciting field to biotechnologists, clinicians, physicians, pharmacists, pharmaceutical chemists, molecular biologists, medicinal chemists, and anyone working in the biotechnological and pharmaceutical industries or in medicinal institutes. It should also be invaluable to undergraduate and graduate students, postdoctoral fellows, and researchers looking for quick, clear, and concise ideas on topics that lie outside their areas of expertise. It also belongs in academic, industrial, and governmental libraries. (The Chemical Educator) This is an extensive and unmatched compilation of comprehensive, in-depth current knowledge and history of biopharmaceuticals...the author is commended for this grand effort. (Veterinary Pathology) I heartly recommend this authoritative, comprehensive reference to this new, exciting field dealing with the entire broad range of available biopharmaceuticals. It will be invaluable to biotechnologists, clinicians, physicians, pharmacists, pharmaceutical chemists, molecular biologists, medicinal chemists and anyone working in the biotechnological and pharmaceutical industries or in medicinal institutes. It should be also be useful for undergraduate and graduate students, postdoctoral fellows, and researchers seeking quick, clear, and concise ideas on topics outside their areas of specialization. it should also find a place in academic, industrial, and governmental libraries. (ChemMedChem) All in all, this is an impressive snapshot of the field. (Journal of Medicinal Chemistry) ... the four volumes represent a highly valuable reference compendium for any practicing scientists interested in this sector of biotechnology. (Chemistry and Industry) Due to the impressive accumulation of outstanding results, presented by brilliant, privileged and creative thinkers, the book reads like the Who is Who of biotechnology. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel Prize laureates Robert Huber, Thomas R. Cech, and Manfred Eigen as well as authors from the world's most famous academic institutes and biotech companies. (BIOforum Europe) Der Herausgeber Dr. JArg KnAblein ist der Leiter der Abteilung Mikrobiologische Chemie bei Schering. Das Werk ist eine einzigartige und umfassende EinfA1/4hrung in die neuere technologische Entwicklung bei Biopharmazeutika, es zeigt die Paradigmenwechsel in der medizinischen Behandlung auf und wie diese VerAnderungen auf die industrielle Forschung ausstrahlen. Die Autoren des Werkes kommen aus den weltweit renommiertesten Forschungsinstituten - darunter die NobelpreistrAger Robert Huber und Thomas R. Cech - und Biotechnologie-Unternehmen. CHEManager Das Werk umfasst vier BAnde mit allein 80-seitigem Executive Summary. Hier wird das heutige Wissen der modernen Wirkstoffentwicklung aus akademischer und Industrieforschung zusammengefA1/4hrt. Von AntikArper bis Zulassungsverfahren: Methoden, Mechanismen, Genregulation und Gesundheitspolitik werden von ausgewiesenen Spezialisten detailliert auf dem neuesten Stand dargestellt. BioRegioN ...ein umfassendes Bild A1/4ber den aktuellen Stand der biotechnologischen Entwicklung auf der Basis molekularbiologischer Wissenschaften... Die beigefA1/4gte CD zum Buch enthAlt unter anderem einige beeindruckende Darstellungen aus dem Institut von Dr. Hwang ... Ebenfalls sind die kompletten Inhaltsverzeichnisse in jedem Band hilfreich. ... molekularbiologische Strukturen und Abbildungen in hoher QualitAt ... Ein umfassendes Werk und Spiegel der derzeit erfolgreichen Pharma-Branche. Umwelt und Gesundheit Vier BAnde, 1886 Seiten, 4,5 Kilogramm Lebendgewicht: Modern Biopharmaceuticals beansprucht, rein optisch gesehen, viel Platz. Inhaltlich ist damit der Anspruch auf VollstAndigkeit verbunden. In der Tat decken die BeitrAge ein extrem breites Themenspektrum ab, das seinesgleichen sucht...Nicht nur inhaltlich, sondern auch unter formalen Gesichtspunkten kann das Buch punkten. Die einzelnen Kapitel illustrieren die Themen teilweise an instruktiven Fallbeispielen und sind im Detail prAzise, ohne sich in NebensAchlichkeiten zu verlieren... Unternehmen, Organisationen und BehArden, die sich im weitesten Sinne mit Biotechnologie und Biopharmazeutika befassen ... investieren sinnvoll ... Nachrichten aus der Chemie Ein wirklich beeindruckendes Werk. Wenn man sich A1/4ber Wochen mit den vier BAnden beschAftigt und dazu noch die eindrucksvollen PrAsentationen und Filme der beiliegenden CD angesehen hat, kommt man zu dem Schluss, dass die zu Beginn zitierten Marketingaussagen absolut zutreffend sind. Dieses Werk ist ein Guiness Buch der Biotechnologie, von der ersten bis zur letzten Seite spannend und lehrreich, geeignet fA1/4r den Studenten wie fA1/4r den Dozenten, fA1/4r den Grundlagenforscher wie fA1/4r den Entwickler. Mit nahezu 400 Graphiken gut bebildert, bleibt neben der hohen Informationsdichte auch immer Platz fA1/4r die didaktischen AnsAtze. Es ist zu hoffen und zu erwarten, dass diese vier BAnde A1/4ber Design, Entwicklung und Optimierung von modernen biopharmazeutischen Produkten in den wissenschaftlichen Instituten und den BA1/4ros der pharmazeutischen und biotechnologischen Industrie Einzug halten werden. Arzneimittel-Forschung / Drug Research Dem Herausgeber ist mit diesem Werk gelungen, das gesamte Spektrum der Biopharmazeutika umfassend abzudecken, weshalb man heute vom Guiness-Buch der Biotechnologie spricht. Pharmazie in unserer Zeit
...a fine addition to library shelves in academic and corporate libraries...this is an impressive snapshot of the field. (Journal of Medicinal Chemistry, August 10, 2006) This is an extensive and unmatched compilation of comprehensive, in-depth current knowledge and history of biopharmaceuticals...the author is commended for this grand effort. (Veterinary Pathology, May 2006) ...an impressive compilation of outstanding results written by brilliant, creative thinkers who are shaping present and future biotechnology. (The Chemical Educator, May/June 2006)
Author Information
Dr. Jorg Knablein studied Biotechnology / Chemical Engineering at the Society for Biotechnology Research (GBF) in Braunschweig, Germany and Biochemistry at the Max-Planck-Institute for Biochemistry. He received his Ph.D. from the Max-Planck-Institute for Biochemistry in Martinsried / Munich where he worked in the group of Professor Huber (Nobelprize laureate in 1988). AWARDS: Riedel-de Haen-Stiftung Government / Ministry of Science Nomination for the Max-Buchner-Award from DECHEMA (Society for Biotechnology and Chemical Engineering) Winner of the McKinsey business plan contest
